Orelia Wood
Family · Houston, TXNPI 1316417470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,038 and has fallen 64.7% since, to $720 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $111.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$874
- Esperion Therapeutics, Inc.$352
- Sobi, Inc$249
- Gilead$226
- Ultragenyx Pharmaceutical Inc.$226
- plus $4K from 28 others
What the payments were for
- Food & beverage$6,708100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $1,236 |
| AbbVie | 8 | $874 |
| Esperion Therapeutics, Inc. | 3 | $352 |
| Sobi, Inc | 3 | $249 |
| Gilead(2 entities) | 2 | $226 |
| Ultragenyx Pharmaceutical Inc. | 2 | $226 |
| Daiichi Sankyo Inc. | 2 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $216 |
| Novo Nordisk | 2 | $179 |
| Stemline Therapeutics Inc. | 1 | $155 |
| Ferring Pharmaceuticals Inc. | 1 | $152 |
| Sanofi | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Pharmacosmos Therapeutics Inc. | 1 | $122 |
| Genentech USA, Inc. | 1 | $121 |
| Kyowa Kirin, Inc. | 1 | $121 |
| Johnson & Johnson | 1 | $120 |
| Sun Pharmaceutical Industries Inc. | 1 | $120 |
| Pfizer | 1 | $119 |
| Myovant Sciences Inc. | 1 | $116 |
| Regeneron Healthcare Solutions, Inc. | 1 | $113 |
| Ascendis Pharma Endocrinology Inc | 1 | $112 |
| Syndax Pharmaceuticals, Inc. | 1 | $106 |
| Astellas Pharma US Inc | 1 | $104 |
| Pharmaessentia USA Corporation | 1 | $103 |
| Organon | 1 | $102 |
| Edwards Lifesciences | 1 | $101 |
| Bayer | 1 | $96 |
| Teva Pharmaceuticals USA, Inc. | 1 | $95 |
| Bristol Myers Squibb | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,708 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in Houston
- Robin BeachHouston$428K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- Kendrick ClackHouston$28K
- David WeirDallas$959K
- April LopezMcAllen$417K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.